Authorization

The FDA just approved a drug that targets cancers based on DNA, rather than where the tumor is in your body

The FDA just approved a drug that targets cancers based on DNA, rather than where the tumor is in your body
REUTERS/Suzanne Plunkett



The FDA just approved a new cancer treatment in an unconventional way: not by tumor type, but rather by the genetic mutation the drug targets.




The drug, Vitrakvi, was developed by Loxo Oncology in partnership with pharma giant Bayer.




It's only the second time the FDA has approved a cancer drug's use based on a certain mutation rather than a particular tumor type.



The Food and Drug Administration just took an unconventional approach to approving a new cancer drug.
The drug, Vitrakvi, was developed by Loxo Oncology. It's the company's first drug to get approved.
Loxo's approach is to develop drugs that act on cancerous genetic mutations rather than the type of cancer a person has. For example, Vitrakvi, has been tested in patients with lung, colon, breast and thyroid cancer among others.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930